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Abstract
Background: Management of glioblastoma multiforme (GBM) has been difficult using standard therapy (radiation 
with temozolomide chemotherapy). The ketogenic diet is used commonly to treat refractory epilepsy in children and, 
when administered in restricted amounts, can also target energy metabolism in brain tumors. We report the case of a 
65-year-old woman who presented with progressive memory loss, chronic headaches, nausea, and a right hemisphere 
multi-centric tumor seen with magnetic resonance imaging (MRI). Following incomplete surgical resection, the patient 
was diagnosed with glioblastoma multiforme expressing hypermethylation of the MGMT gene promoter.
Methods: Prior to initiation of the standard therapy, the patient conducted water-only therapeutic fasting and a 
restricted 4:1 (fat: carbohydrate + protein) ketogenic diet that delivered about 600 kcal/day. The patient also received 
the restricted ketogenic diet concomitantly during the standard treatment period. The diet was supplemented with 
vitamins and minerals. Steroid medication (dexamethasone) was removed during the course of the treatment. The 
patient was followed using MRI and positron emission tomography with fluoro-deoxy-glucose (FDG-PET).
Results: After two months treatment, the patient's body weight was reduced by about 20% and no discernable brain 
tumor tissue was detected using either FDG-PET or MRI imaging. Biomarker changes showed reduced levels of blood 
glucose and elevated levels of urinary ketones. MRI evidence of tumor recurrence was found 10 weeks after suspension 
of strict diet therapy.
Conclusion: This is the first report of confirmed GBM treated with standard therapy together with a restricted 
ketogenic diet. As rapid regression of GBM is rare in older patients following incomplete surgical resection and 
standard therapy alone, the response observed in this case could result in part from the action of the calorie restricted 
ketogenic diet. Further studies are needed to evaluate the efficacy of restricted ketogenic diets, administered alone or 
together with standard treatment, as a therapy for GBM and possibly other malignant brain tumors.
Introduction
Glioblastoma multiforme (GBM) is the most malignant
primary brain tumor in adults and children. Conventional
GBM therapies are considered palliative, but rarely cura-
tive. Long-term progression free survival remains low for
most GBM patients even after complete surgical excision,
combined with the best available treatment [1]. Standard
therapy for GBM includes surgery followed by concomi-
tant radiation and/or chemotherapy. These procedures,
however, extend median survival by only a few months
beyond the no therapy option [2]. In general, survival is
better for younger patients than for older patients and
also for those patients with promoter hypermethylation
of the O6-methylguanine methyltransferase (MGMT)
gene [1,3]. Although numerous somatic mutations occur
in GBM, no new therapies are yet available to exploit this
information for enhanced patient survival [4]. The pres-
ence of numerous mutations in GBM tumor cells will,
however, restrict metabolic flexibility thus enhancing sus-
ceptibility of the tumor cells to energy stress according to
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Page 2 of 7principles of evolutionary biology and metabolic control
theory [5-7].
A high glycolytic rate with lactic acid production,
resulting largely from impaired respiratory function, is a
primary metabolic phenotype of GBM and of most can-
cers [5,6,8]. In contrast to normal brain cells, which
evolved to metabolize ketone bodies for energy when glu-
cose levels are reduced, most brain tumor cells are depen-
dent on glycolysis for survival and are unable to
metabolize ketone bodies for energy due to impaired
mitochondrial function [9]. This metabolic deficiency
allows the tumor cells to be metabolically isolated from
normal cells. A strong dependence on glucose makes the
tumor cells vulnerable to death using therapies that target
glucose metabolism. The ketogenic diet, administered in
restricted amounts, is ideally suited as a non-toxic meta-
bolic therapy for managing malignant brain cancer
because the diet naturally lowers circulating glucose lev-
els while elevating levels of ketone bodies [9-11]. The
ketogenic diet (KD) is a high fat, low carbohydrate diet
that has been used for decades as an effective therapy for
refractory seizures in children [6,12-14]. Otto and co-
workers showed that a KD supplemented with omega-3
fatty acids and medium-chain triglycerides could delay
growth of human gastric cancer cells in nude mice [15],
while Freedland and co-workers have considered the role
for low-carbohydrate KD in the management of prostate
cancer [16]. The KD also has disease-modifying activity
against neurodegenerative disorders and protective
action against brain trauma and ischemic injuries [11,17-
19]. Hence, the ketogenic diet administered in restricted
amounts (R-KD) has potential as a non-toxic metabolic
therapy against malignant brain cancer.
While dietary restriction and restricted ketogenic diet
therapy is effective in targeting tumor energy metabolism
and angiogenesis in experimental animal models
[9,11,20-23], no studies have evaluated the efficacy of
restricted ketogenic diets as a therapy for older patients
with GBM. An earlier report, however, showed that the
KD was effective in managing growth and enhancing pro-
gression free survival in two children with malignant
brain tumors that were refractory to radiation and che-
motherapy [10]. In this study, we used neuro-imaging to
describe the response of a 65 year-old female GBM
patient treated with standard therapy together with a
restricted ketogenic diet.
Case Report
A 65 year-old-female was admitted to Arcispedale Santa
Maria Nuova, Reggio, Italy on December 5th, 2008 who
presented with progressive memory loss, chronic head-
aches, and nausea. The symptoms were present, off-and-
on, for about one month prior to diagnosis. Neurological
examination showed mild left superior harm and facial
paresis. The patient's family history included breast ade-
nocarcinoma (mother), and ovarian carcinoma (sister).
Past clinical history included post-pubertal headache,
hysterectomy at the age of 37 years, chronic erosive gas-
tritis and familial hypercholesterolemia controlled with
lipid-lowering medication. The patient's blood pressure
was 120/70, and within normal limits. Laboratory tests
revealed an unremarkable complete blood count. Liver
and renal functions were within normal limits. Blood bio-
chemistry was essentially normal. Prior to therapeutic
intervention, the patient's weight and height, were 64
kilograms (kg) (141 pounds) and 158 centimetres (62
inches), respectively. This height and weight related to an
approximate body mass index (BMI) of 25.6 kg/m2.
On the day of admission, the patient underwent con-
trast-enhanced (contrast media: gadoteric acid, 0.2 ml/
kg) magnetic resonance imaging (MRI), which disclosed a
large multi-centric solid necrotic tumor in the right
hemisphere (Figure 1). The tumor showed extensive infil-
tration of the right temporal pole, the insular lobe, the
frontal operculum, the putamen, and head of the caudate
nucleus. Avid contrast enhancement characterized the
tumor, which was surrounded by extensive edema. A shift
to the left of the midline structures was noted. The tumor
also compressed the right frontal horn. An electroen-
cephalogram demonstrated abnormality with a general-
ized slowing background and frequent delta bursts on the
right frontotemporal region. Anti-inflammatory steroidal
therapy (dexamethasone, 16 mg/day i.v.) and anti-epilep-
tic therapy (Topiramate, 50 mg/2×/day and Clobazam, 50
mg/day) were commenced. On December 15th, the
patient underwent right frontal temporal craniotomy
involving partial excision of the temporal pole with
incomplete debulking.
The histopathological examination disclosed the pat-
terns of GBM. Haematoxylin and eosin (H&E) analysis
showed high cellularity, prominent vascularity, as well as
areas of necrosis and hemorrhage. The tumor cells
appeared poorly differentiated, hyperchromatic, pleo-
morphic, and displayed neoplastic pseudopalisades sur-
Figure 1 MRI contrast enhanced images of a large multi-centric 
mass involving the right hemisphere pole. (A) Temporal pole, (B) 
frontal operculum, insular lobe, posterior putamen, (C)  frontal opercu-
lum, head of caudate nucleus. Note the presence of peripheral edema 
(arrows).
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infiltration was also noted. The histological characteris-
tics were typical for GBM (WHO grade IV) [24,25].
Methylation of the O6-methylguanine-DNA methyltrans-
ferase (MGMT) promoter was also detectable according
to standard procedures [26]. The patient underwent com-
puted tomography (CT) of the head during the immedi-
ate postoperative period, which showed an increasing
edema-related shift to the left of the midline structures.
During the immediate post-operative recovery period,
the patient started a self-imposed water only fast (from
December 16-17). The patient's average daily calorie
intake, prior to fasting, was about 1700-1800 kcal/day.
Blood glucose was 130 mg/dl while urine ketone levels
were undetectable. After several days of modest food
consumption, the patient again started a water-only fast
on December 22. Blood glucose and urine ketones were
monitored using a standard glucose kit and Keto-Stick kit
(Ketur-Test®). After three days of fasting (ketosis induc-
tion period), ketones were raised to the high level of +++,
while blood glucose was reduced to 60 mg/dl. At this time
(December 24), the patient's body weight and body mass
index was 58.0 kg (127.6 lbs) and 23.23 kg/m2, respec-
tively. After the fast, a KD was administered in restricted
amounts for 14 days (December 24 to January 7, 2009).
This calorie restricted ketogenic diet (R-KD) delivered
about 600 kcal/day in total and included 20 g of the Keto-
Cal® 4:1 (fat/protein + carbohydrate) diet (SHS, Interna-
tional), 10 g medium chain triglyceride oil (MCT), 32 g
protein, and 10 g carbohydrates. The diet contained a
small amount of dietary fiber, and a total fat content of 42
g. The R-KD was supplemented with multivitamins
including the B complex and minerals to maintain nutri-
ent adequacy and to avoid metabolic abnormalities as
previously described [27].
After 14 days of the R-KD, the concomitant radiation
plus chemotherapy (temozolomide) regimen was initi-
ated on January 8, 2009, according to standard proce-
dures [2]. All steroidal medication was terminated at this
time. The patient's body weight was 55 kg (121 lbs) at the
start of the standard treatment, which extended to Febru-
ary 17, 2009. On January 27, the patient developed a mild
hyperuricemia of 6.2 mg/dl (normal values: 2.4-5.7 mg/
dl). The plasma uric acid levels gradually increased reach-
ing a maximum value of 10.9 mg/dl by February 7. Tran-
sient hyperuricemia can occur following implementation
of ketogenic diets [28]. Allopurinol (100/mg/day) treat-
ment was commenced to control the uric acid levels,
which gradually returned within normal ranges. Due to
the hyperuricemia the patient was gradually shifted to a
calorie restricted non-ketogenic diet, which also deliv-
ered a total of about 600 kcal/day. This diet maintained
low blood glucose levels and slightly elevated (++) urine
ketone levels due to the low calorie content of the diet.
The changes in circulating glucose and ketone levels dur-
ing this period are shown in Figure 3. More comprehen-
sive blood analysis was not conducted. It is important to
mention that the patient did not experience hypoglyce-
mia (blood glucose levels below 45 mg/dl) at any time
during the course of fasting or ketogenic diet therapy.
During the concomitant chemotherapy, laboratory tests
revealed abnormalities in complete blood count to
Figure 2 Histopathological analysis of excised brain tumor tissue 
(H&E). A) Multiple zones of necrosis circumscribed by viable tissue (4 
×). B) Dense zone of small-cells with hyperchromatic nuclei and scant 
cytoplasm (10 ×). C) Zone of necrosis with dense pseudopalisades of 
small tumor cells at the periphery (20 ×). D) Tumor cell infiltration of the 
subpial zone of the cortex (20 ×).
Figure 3 Levels of circulating glucose (black line) and urinary ke-
tones (red line) in the patient during the period from January 8 to 
February 7, 2009. The values are within normal physiological ranges 
for people who maintain low calorie dieting [46].
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million/mm3, hemoglobin 10.5 g/dl, and hematocrit 32%.
The patient also developed lymphopenia 0.332 ×1000/
mm3. The concomitant treatment was terminated on
February 17th. One week later (February 24, 2009), the
patient underwent an MRI. No evidence of either the
tumor or the associated edema was apparent (Figure 4).
Porencephaly was seen in the right frontal region at the
tumor site. Ex vacuum enlargement of the right frontal
horn and lack of mass effect represented indirect confir-
mation of tumor regression. Restitutio ad Integrum of the
insular lobe, caudate nucleus, and putamen were noted
with only minimal damage to the blood brain barrier
(Figure 4). On March 3, the patient developed mild hypo-
proteinemia (5.1 g/dl). This was corrected by increasing
dietary protein to about 7 g/day for one month, which
returned protein levels to the normal range (6.4 gr/dl).
On April 21, the patient underwent positron emission
tomography with fluoro-deoxy-glucose (FDG-PET),
which included delayed acquisition. No evidence of
recurrent disease was detected (Figure 5). An MRI, per-
formed on July 22, was stable over the comparison time
from February 24 with no clear evidence of disease recur-
rence. At that time, the patient weighed 50 kg (110
pounds, BMI 20.0 kg/m2), was in good general health,
and had no neurological complications. The patient's
Karnofsky performance status was at 100% during the
course of the diet. Caloric intake was not strictly followed
after July 22. An MRI performed on October 9, 2008
showed tumor recurrence. The patient was then treated
with CPT11 (Irinotecan) and bevacizumab (Avastin)
therapy. A schematic diagram showing the clinical time
course of dietary treatments with dates of MRI and PET
is presented in Figure 6.
Discussion
In this case report we describe the management of a
highly invasive multi-centric GBM in an older patient fol-
lowing partial tumor resection and treatment with a com-
bination of standard therapy, fasting, and a R-KD. The
patient's response to this therapeutic approach was
unusual, as no prior reports have appeared to our knowl-
edge describing regression of GBM within 2.5 months
from the time of diagnosis in either younger (< 50 yrs) or
older (> 50 yrs) patients using standard radiation and
temozolomide therapy alone. Although the patient in this
study expressed hypermethylation of the MGMT gene
promoter, which enhances the therapeutic action of
temozolomide and is prognostic for increased survival
[26], no prior cases of rapid GBM regression have been
reported in patients with the MGMT hypermethylation
phenotype to our knowledge. Temozolomide is an oral
alkylating agent that damages DNA and is used as first
and second line GBM treatment [2,26,29]. Continuous
temozolomide administration depletes O6-methylgua-
nine-DNA methyltransferase, which is required for
repairing DNA damage. Based on the MRI and PET-CT
data, we speculate that the combined conventional and
metabolic approach to GBM management in this patient
enhanced early MGMT related cytotoxicity and apopto-
sis. Further studies in additional patients will be needed
to support this hypothesis.
The response of the GBM in this older female patient to
the therapeutic action of the R-KD was similar to that
reported previously in children with malignant brain
tumors treated with a medium-chain triglyceride keto-
genic diet [6,10]. High dosage steroid medication for
brain cancer patients increases gluconeogenesis and
blood glucose levels while enhancing apoptosis resistance
in tumor cells [6,30,31]. We eliminated dexamethasone
administration soon after surgery in our patient, as calo-
rie restriction and the R-KD can also target inflammation
without elevating blood glucose levels [6,30]. We consider
that dexamethasone, which induces hyperglycemia, could
Figure 4 Brain MRI taken a few days after ending the standard ra-
diotherapy plus concomitant  temozolomide therapy together 
with KD-CR protocol. No clear evidence of tumor tissue or  associated 
edema was seen. Arrow indicates porencephaly.
Figure 5 Positron emission tomography with fluoro-deoxy-glu-
cose (FDG-PET) imaging  showing no evidence of recurrent tu-
mor.
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findings in our patient are anecdotal, we cannot exclude
the possibility that the management observed was related
to the elimination of steroids and the combined action of
standard therapy with early implementation of a novel
metabolic therapy involving fasting, a R-KD, and calorie
restriction.
It is well documented that brain tumor growth in mice
is dependent to a large extent on circulating levels of glu-
cose [11,32]. The same phenomenon also appears to be
the case for human brain cancer patients, as reduced sur-
vival is associated with high blood glucose levels [33-35].
Glucose levels in brain are correlated with glucose levels
in blood, but glucose concentration is lower in brain than
in blood [36]. High circulating glucose levels accelerate
brain tumor growth and angiogenesis while also prevent-
ing apoptosis through activation of the IGF-1/PI3K/Akt/
Hif-1a signalling pathways [11,21]. Reductions in circu-
lating glucose levels reverse these processes leading to
reduced tumor growth [5,7,9,21]. Studies in mice also
show that the therapeutic action of R-KD can be
enhanced when combined with the glycolysis inhibitor, 2-
deoxyglucose, for management of malignant astrocytoma
[37]. Hence, pharmacological inhibition of glycolysis,
while maintaining low circulating glucose levels (within
normal physiological ranges), could be therapeutically
beneficial to brain cancer patients.
Besides reducing inflammation, ketone bodies provide
an alternative metabolic fuel for normal brain cells when
glucose levels are reduced, and thus protect normal brain
cells from the energy stress of reduced glucose levels
[6,7]. Although long-term use of ketogenic diets can
sometimes produce adverse effects (gastrointestinal dis-
turbances, renal stones, etc) [12,38], these are generally
mild and can be significantly reduced if the diet is con-
sumed in restricted amounts. No adverse effects on neu-
rological or physiological function were observed during
the course of the metabolic therapy in our patient. Previ-
ous studies in rats also showed that calorie restriction
could reduce inflammation while improving macrophage
function suggesting improvements in some aspects of
host immunity [39]. It is therefore unlikely that the R-KD
would compromise host immune function. As long as the
KD is consumed in restricted amounts, there should be
no adverse effects on normal physiological functions.
In contrast to normal brain cells, the tumor cells are
largely unable to metabolize ketone bodies for energy due
to mitochondrial defects [9,30,40]. Moreover, recent
studies in a variety of cultured human tumors cells show
that ketone bodies inhibit the viability of tumor cells, but
not of normal cells, suggesting that ketone bodies could
inhibit tumor cell growth through multiple mechanisms
[41,42]. The numerous mutations expressed in the tumor
cells reduce metabolic flexibility thus rendering the
tumor cells vulnerable to the therapeutic action of the R-
KD [5,7].
The findings from our patient suggest that therapies,
which lower blood glucose levels while elevating ketone
body levels, could be an effective non-toxic therapy for
increasing progression free survival in patients with
malignant brain tumors. While our patient did not main-
tain blood glucose levels considered maximal for thera-
peutic efficacy (55-65 mg/dl) [7], the levels were reduced
to low normal range. It is important to mention that mea-
surement of urinary ketones is less predictive of physio-
logical ketosis than is measurement of blood ketones.
Although blood ketone levels can be correlated with uri-
nary ketone levels, the correlation is not always accurate
[43,44]. Consequently, measurements of blood ketone
levels are recommended for future studies of ketosis state
and therapeutic success in brain cancer patients. The
combined action of reduced blood glucose together with
elevated blood ketone levels could provide an effective
complimentary or alternative non-toxic therapy for per-
sons with malignant brain cancer. Clinical trials for keto-
genic diet therapy for brain cancer management could be
designed in a similar manner to those previously used for
the management of epilepsy [45].
Conclusion
This case report is remarkable for a number of reasons.
First, this patient demonstrated that the R-KD was well
Figure 6 Timeline of clinical course with dates of dietary treatments, MRI, and PET
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adjuvant treatment for GBM in adults. Second, the
response of the GBM in this patient after standard treat-
ment alone would be unlikely, further suggesting a role
for targeting energy metabolism as part of the manage-
ment strategy. Third, suppression of edema was achieved
during the concomitant radiation and chemotherapy
treatment without steroids, supporting the anti-inflam-
matory activity of calorie restriction and the R-KD.
Finally, an established mechanism of action based on
defective mitochondrial function in tumor cells can
account for the potential therapeutic efficacy of the R-
KD. In conclusion, further studies are required to deter-
mine the therapeutic significance of R-KD for general
management of human GBM.
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